MBX Biosciences, Inc. (NASDAQ:MBX) Receives Average Recommendation of “Moderate Buy” from Analysts

MBX Biosciences, Inc. (NASDAQ:MBX) has earned a consensus recommendation of “Moderate Buy” from the twelve analysts that are currently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating and ten have assigned a buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $51.5556.

Several equities research analysts recently issued reports on the stock. TD Cowen restated a “buy” rating on shares of MBX Biosciences in a research report on Thursday, March 12th. The Goldman Sachs Group assumed coverage on shares of MBX Biosciences in a research note on Thursday, December 4th. They issued a “sell” rating and a $18.00 price target for the company. Barclays started coverage on shares of MBX Biosciences in a research report on Tuesday, January 27th. They set an “overweight” rating and a $66.00 price target on the stock. Wall Street Zen upgraded MBX Biosciences from a “sell” rating to a “hold” rating in a report on Sunday, December 21st. Finally, Guggenheim increased their price objective on MBX Biosciences from $77.00 to $88.00 and gave the stock a “buy” rating in a research report on Friday, January 16th.

Insider Buying and Selling at MBX Biosciences

In other MBX Biosciences news, CEO P. Kent Hawryluk purchased 18,500 shares of the stock in a transaction dated Friday, March 13th. The stock was acquired at an average cost of $28.41 per share, for a total transaction of $525,585.00. Following the acquisition, the chief executive officer owned 486,777 shares in the company, valued at $13,829,334.57. This trade represents a 3.95% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 52.19% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Hudson Bay Capital Management LP purchased a new stake in shares of MBX Biosciences in the 3rd quarter valued at approximately $1,488,000. Sio Capital Management LLC acquired a new stake in MBX Biosciences in the 2nd quarter valued at approximately $2,750,000. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in MBX Biosciences in the 3rd quarter valued at approximately $498,000. Resolute Capital Asset Partners LLC purchased a new stake in MBX Biosciences in the second quarter valued at approximately $567,000. Finally, Walleye Capital LLC boosted its position in shares of MBX Biosciences by 116.5% during the second quarter. Walleye Capital LLC now owns 70,333 shares of the company’s stock worth $802,000 after buying an additional 37,843 shares during the period.

MBX Biosciences Stock Performance

NASDAQ MBX opened at $32.29 on Thursday. The stock’s fifty day moving average is $33.60 and its two-hundred day moving average is $28.08. The firm has a market capitalization of $1.53 billion, a P/E ratio of -13.40 and a beta of 1.25. MBX Biosciences has a fifty-two week low of $4.81 and a fifty-two week high of $44.89.

MBX Biosciences (NASDAQ:MBX) last issued its earnings results on Thursday, March 12th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.15.

MBX Biosciences Company Profile

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.